Next-generation sequencing (NGS) has been proposed as a comprehensive tool for genomic profiling, enabling the simultaneous detection of multiple gene mutations, including BRAF, as well as an assessment of MSI status and tumor mutational burden (TMB) [14]. This evidence concerns the gene BRAF and neoplasm.